[PRESENTATION] Evaluating Gene Therapy Assets in Preclinical Models

Authors' picture

By Experimentica on September 7, 2022

Summary: Dr. Simon Kaja will present at the Gene Therapy for Ophthalmic Disorders conference 2022.


Experimentica’s CSO and VP, Americas Dr. Simon Kaja will give a presentation about relevant preclinical animal models available to evaluate gene therapy assets at the 3rd Gene Therapy for Ophthalmic Disorders conference in Boston on September 14-15, 2022.

Specifically, Dr. Kaja will present:

  • Species considerations for drug development of ocular gene therapy assets
  • Ocular routes of delivery for gene therapy in preclinical models
  • Efficacy and safety assessment of gene therapy assets in preclinical ocular models

The conference offers world class content, with two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Experimentica is proud to sponsor this year’s edition of the conference. Full program available here.

Authors' picture